Brainsway Ltd. has announced its financial results for the third quarter of 2026, showcasing significant growth and a strategic focus on expanding its market presence in the interventional psychiatry sector. The report, filed on November 10, 2026, highlights a remarkable 34% increase in revenue compared to the same quarter last year, along with substantial improvements in operating income and EBITDA. This update is crucial for understanding Brainsway's ongoing efforts to solidify its leadership position in the surgical and medical instruments industry.

Background

Brainsway Ltd. is a company primarily involved in the development and marketing of advanced medical technologies, particularly in the field of interventional psychiatry. The company operates under the Standard Industrial Classification (SIC) code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Brainsway trades on the Nasdaq under the ticker symbol BWAY and is also listed on the OTC market under BRSYF. Recent filings include multiple 6-K forms, with the latest filed on November 10, 2026, under accession number 0001171843-26-007332.

What the Filing Says

The filing indicates that Brainsway achieved a revenue of $18.1 million in Q3 2026, up from $13.5 million in Q3 2025. The operating income surged to $2.6 million, a 107% increase year-over-year, while EBITDA rose to $3.9 million, reflecting a 92% growth. The company also reported a cash balance of $63.4 million and a backlog of $85 million, indicating strong demand for its products.

Impact

This financial performance may impact various stakeholders, including investors, healthcare providers, and competitors in the surgical and medical instruments sector. With the reported growth, Brainsway is positioned to attract more investment and potentially influence market dynamics as it continues to lead in interventional psychiatry technologies.

What's Next

The filing does not specify what happens next, but Brainsway's ongoing focus on innovation and market expansion is likely to drive future developments. The company may continue to release further updates as it progresses through the fourth quarter of 2026 and beyond.